Literature DB >> 2582776

Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results.

D Kampf1, A Kahl, J Passlick, A Pustelnik, K U Eckardt, B Ehmer, C Jacobs, A Baumelou, B Grabensee, G M Gahl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2582776     DOI： 10.1159/000417886

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  10 in total

1.  The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.

Authors:  Danielle N McLennan; Christopher J H Porter; Glenn A Edwards; Anne C Heatherington; Steven W Martin; Susan A Charman
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

2.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

Review 3.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

4.  Subcutaneous r-HuEPO therapy in CAPD patients: dose determination and clinical experience.

Authors:  L Janicka; A Ksiazek; I Baranowicz; A Bednarek-Skublewska; P Mierzicki; P Ksiazek
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 5.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

6.  The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.

Authors:  J D Jensen; L W Jensen; J K Madsen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Authors:  I C Macdougall; D E Roberts; G A Coles; J D Williams
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

8.  Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment.

Authors:  J P Schouten; G Voorhorst; A R Helbing; J W Janssen; P P Diderich; C T Op de Hoek
Journal:  Pharm World Sci       Date:  1993-12-17

9.  The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

Authors:  J Brockmöller; J Köchling; W Weber; M Looby; I Roots; H H Neumayer
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

10.  Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.

Authors:  Jorge F Pérez-Oliva; Martha Casanova-González; Idrian García-García; Pedro J Porrero-Martín; Carmen M Valenzuela-Silva; Tairí Hernández-Montero; Marcia Lagarde-Ampudia; Yuri Casanova-Kutsareva; Yisel Avila-Albuerne; Alicia Vargas-Batista; Hailen Bobillo-López; Raúl Herrera-Valdés; Pedro A López-Saura
Journal:  BMC Nephrol       Date:  2005-05-23       Impact factor: 2.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.